{"id":29430,"date":"2023-07-17T15:00:07","date_gmt":"2023-07-17T19:00:07","guid":{"rendered":"https:\/\/www.cancerresearch.org\/?post_type=cri_scientists&#038;p=29430"},"modified":"2024-08-27T11:33:15","modified_gmt":"2024-08-27T15:33:15","slug":"inaki-etxeberria-phd","status":"publish","type":"cri_scientists","link":"https:\/\/www.cancerresearch.org\/es\/cri-funded-scientists\/inaki-etxeberria-phd","title":{"rendered":"Inaki Etxeberria, PhD"},"content":{"rendered":"\n<p>Dr. Inaki Etxeberria is investigating strategies to target immunotherapy-resistant cancers that express a mutated version of an important growth-promoting gene.<\/p>\n\n\n\n<p>Although some patients experience long-lasting benefit with current cancer immunotherapies, many fail to respond or end up progressing after initially responding. More than 25% of melanomas, as well as some colorectal cancers, harbor mutated versions of NRAS, a growth-related pathway that can drive cancer progression. Patients with mutated NRAS are less likely to respond to immunotherapy, and therefore new therapies are urgently needed for people with these cancers. A major gap in knowledge that is limiting NRAS-based immunotherapy approaches is the need to identify immune-stimulating targets that are selectively expressed only by tumor cells.<br><br>Recently, Dr. Exteberria discovered that NRAS mutations generate markers known as neo-antigens that are expressed exclusively by the tumor cells, and now he\u2019s working to develop T cell receptor (TCR)-based immunotherapies to target these cancers with mutated NRAS. Using a unique collection of samples from patients whose tumors express mutated NRAS, he has generated T cells specific for this mutation and confirmed their ability to effectively target the cancer cells. Moving forward he\u2019s focused on optimizing this cell therapy approach to target melanoma and other common cancers with genetic features linked to immunotherapy resistance. Overall, these studies should generate new generalizable knowledge that improves our understanding of how the adaptive immune system can distinguish between normal and cancerous tissues.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Projects and Grants<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\"><strong><strong>Immunogenic landscape and therapeutic targeting of NRAS \u00abpublic\u00bb neoantigens<br><\/strong><\/strong><\/h3>\n\n\n\n<p>Memorial Sloan Kettering Cancer Center | Melanoma, Colorectal cancer | 2023 | Christopher Klebanoff, MD<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Dr. Inaki Etxeberria is investigating strategies to target immunotherapy-resistant cancers that express a mutated version of an important growth-promoting gene. Although some patients experience long-lasting benefit with current cancer immunotherapies, many fail [&hellip;]<\/p>\n","protected":false},"featured_media":29422,"template":"","tax_cancer_type":[362,354],"tax_grant_type":[486],"tax_award_year":[480],"tax_institutions":[493],"tax_location_states":[494],"class_list":["post-29430","cri_scientists","type-cri_scientists","status-publish","has-post-thumbnail","hentry"],"acf":{"scientist_subhead":"CRI Postdoctoral Fellow","quote":"I'm honored to receive CRI support for my research on T cell responses to public neo-antigens. Our goal is to develop a new class of TCR-based therapies for cancers that urgently need better treatments.","scientist_last_name":"Etxeberria","show_on_landing":false,"scientist_publish_until":"20260831"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Inaki Etxeberria, PhD<\/title>\n<meta name=\"description\" content=\"Dr. Inaki Etxeberria is investigating strategies to target immunotherapy-resistant cancers that express a mutated version of an important growth-promoting gene.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/inaki-etxeberria-phd\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Inaki Etxeberria, PhD\" \/>\n<meta property=\"og:description\" content=\"Dr. Inaki Etxeberria is investigating strategies to target immunotherapy-resistant cancers that express a mutated version of an important growth-promoting gene.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/inaki-etxeberria-phd\" \/>\n<meta property=\"og:site_name\" content=\"Cancer Research Institute\" \/>\n<meta property=\"article:modified_time\" content=\"2024-08-27T15:33:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2023\/07\/Etxeberria_Inaki.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1179\" \/>\n\t<meta property=\"og:image:height\" content=\"1179\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/inaki-etxeberria-phd\",\"url\":\"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/inaki-etxeberria-phd\",\"name\":\"Inaki Etxeberria, PhD\",\"isPartOf\":{\"@id\":\"https:\/\/www.cancerresearch.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/inaki-etxeberria-phd#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/inaki-etxeberria-phd#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2023\/07\/Etxeberria_Inaki.jpg\",\"datePublished\":\"2023-07-17T19:00:07+00:00\",\"dateModified\":\"2024-08-27T15:33:15+00:00\",\"description\":\"Dr. Inaki Etxeberria is investigating strategies to target immunotherapy-resistant cancers that express a mutated version of an important growth-promoting gene.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/inaki-etxeberria-phd#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/inaki-etxeberria-phd\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/inaki-etxeberria-phd#primaryimage\",\"url\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2023\/07\/Etxeberria_Inaki.jpg\",\"contentUrl\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2023\/07\/Etxeberria_Inaki.jpg\",\"width\":1179,\"height\":1179,\"caption\":\"Inaki Etxberria\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/inaki-etxeberria-phd#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.cancerresearch.org\/es\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Inaki Etxeberria, PhD\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.cancerresearch.org\/#website\",\"url\":\"https:\/\/www.cancerresearch.org\/\",\"name\":\"Cancer Research Institute\",\"description\":\"For a World Immune to Cancer\",\"publisher\":{\"@id\":\"https:\/\/www.cancerresearch.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.cancerresearch.org\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.cancerresearch.org\/#organization\",\"name\":\"Cancer Research Institute\",\"url\":\"https:\/\/www.cancerresearch.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.cancerresearch.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/05\/logo-gradient.svg\",\"contentUrl\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/05\/logo-gradient.svg\",\"width\":156,\"height\":53,\"caption\":\"Cancer Research Institute\"},\"image\":{\"@id\":\"https:\/\/www.cancerresearch.org\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Inaki Etxeberria, PhD","description":"Dr. Inaki Etxeberria is investigating strategies to target immunotherapy-resistant cancers that express a mutated version of an important growth-promoting gene.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/inaki-etxeberria-phd","og_locale":"es_ES","og_type":"article","og_title":"Inaki Etxeberria, PhD","og_description":"Dr. Inaki Etxeberria is investigating strategies to target immunotherapy-resistant cancers that express a mutated version of an important growth-promoting gene.","og_url":"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/inaki-etxeberria-phd","og_site_name":"Cancer Research Institute","article_modified_time":"2024-08-27T15:33:15+00:00","og_image":[{"width":1179,"height":1179,"url":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2023\/07\/Etxeberria_Inaki.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Tiempo de lectura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/inaki-etxeberria-phd","url":"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/inaki-etxeberria-phd","name":"Inaki Etxeberria, PhD","isPartOf":{"@id":"https:\/\/www.cancerresearch.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/inaki-etxeberria-phd#primaryimage"},"image":{"@id":"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/inaki-etxeberria-phd#primaryimage"},"thumbnailUrl":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2023\/07\/Etxeberria_Inaki.jpg","datePublished":"2023-07-17T19:00:07+00:00","dateModified":"2024-08-27T15:33:15+00:00","description":"Dr. Inaki Etxeberria is investigating strategies to target immunotherapy-resistant cancers that express a mutated version of an important growth-promoting gene.","breadcrumb":{"@id":"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/inaki-etxeberria-phd#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.cancerresearch.org\/cri-funded-scientists\/inaki-etxeberria-phd"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/inaki-etxeberria-phd#primaryimage","url":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2023\/07\/Etxeberria_Inaki.jpg","contentUrl":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2023\/07\/Etxeberria_Inaki.jpg","width":1179,"height":1179,"caption":"Inaki Etxberria"},{"@type":"BreadcrumbList","@id":"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/inaki-etxeberria-phd#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.cancerresearch.org\/es"},{"@type":"ListItem","position":2,"name":"Inaki Etxeberria, PhD"}]},{"@type":"WebSite","@id":"https:\/\/www.cancerresearch.org\/#website","url":"https:\/\/www.cancerresearch.org\/","name":"Cancer Research Institute","description":"For a World Immune to Cancer","publisher":{"@id":"https:\/\/www.cancerresearch.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cancerresearch.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/www.cancerresearch.org\/#organization","name":"Cancer Research Institute","url":"https:\/\/www.cancerresearch.org\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.cancerresearch.org\/#\/schema\/logo\/image\/","url":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/05\/logo-gradient.svg","contentUrl":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/05\/logo-gradient.svg","width":156,"height":53,"caption":"Cancer Research Institute"},"image":{"@id":"https:\/\/www.cancerresearch.org\/#\/schema\/logo\/image\/"}}]}},"fimg_url":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2023\/07\/Etxeberria_Inaki.jpg","_links":{"self":[{"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/cri_scientists\/29430","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/cri_scientists"}],"about":[{"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/types\/cri_scientists"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/media\/29422"}],"wp:attachment":[{"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/media?parent=29430"}],"wp:term":[{"taxonomy":"tax_cancer_type","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/tax_cancer_type?post=29430"},{"taxonomy":"tax_grant_type","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/tax_grant_type?post=29430"},{"taxonomy":"tax_award_year","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/tax_award_year?post=29430"},{"taxonomy":"tax_institutions","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/tax_institutions?post=29430"},{"taxonomy":"tax_location_states","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/tax_location_states?post=29430"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}